|
|
Upfront Briefing
Lilly opened the week with a chequebook, agreeing to acquire Merida Biosciences for up to $2.875B in cash — a Phase 1 autoantibody degrader, priced like a platform. Meanwhile in Munich, ESC handed cardiology-exposed biotech a split verdict on its way out the door. Wainua's full CARDIO-TTRansform dataset explained the miss without softening it, and the read-through runs straight through Alnylam. Friday's consolation prize: Takeda and Protagonist got Mimrylo over the line in polycythemia vera, triggering $275M on the spot.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,711.8 |
(0.2%) |
12.7% |
| Nasdaq 100 |
29,433.4 |
(0.7%) |
16.8% |
| Russell 2000 |
2,972.4 |
(1.4%) |
19.8% |
| Healthcare (XLV) |
171.2 |
(0.2%) |
10.1% |
| Biotech (XBI) |
162.4 |
(3.5%) |
33.6% |
| Nasdaq Biotech (NBI) |
7,119.1 |
(2.7%) |
24.7% |
| Clinical Trials (BBC) |
53.3 |
(3.7%) |
41.6% |
|
- Biotech took it across the board: XBI (3.5%), BBC (3.7%) and NBI (2.7%) against XLV's 0.2% and a 0.2% S&P 500 dip — a 324bp gap between XBI and large-cap healthcare, with no shelter in the cap-weighted index. Jackson Hole repriced September and the whole sector traded as one duration bet. Friday's FDA slate, Mimrylo and the Mounjaro CV label, landed as single-name events with no index lift.
- The macro driver was Fed Chair Kevin Warsh's first Jackson Hole keynote, read as hawkish: he told the symposium that better summer PCE and CPI prints did not signal improving underlying trends. September hike odds rose, VIX jumped 6.1% to 15.30, the 10-year backed up to 4.750% and TLT slipped 0.3%, with the Russell 2000 off 1.4%.
- Market data: U.S. cash close Friday, 28 August 2026.
The Big 3
|
1
|
Lilly pays up to $2.875B for Merida and a Phase 1 autoantibody degrader
|
- Lilly signed a definitive agreement to acquire Merida Biosciences for up to $2.875B in cash, inclusive of upfront and contingent milestones, with close expected in Q4 2026.
- Why it matters: $2.875B for a Phase 1 asset is Lilly paying platform prices on single-digit clinical data. MER511 degrades pathogenic thyroid-stimulating antibodies rather than blocking FcRn recycling, and that distinction is the whole thesis: argenx's Vyvgart, J&J's nipocalimab and Immunovant's IMVT-1402 all lower IgG indiscriminately, while Graves' disease with thyroid eye disease is exactly where selective degradation should separate. Tepezza is the commercial comp Lilly is aiming at. MER769 extends the same chemistry into IgE-driven allergy, which is the option value. Risk is stage — titre reductions are a biomarker, not an outcome, and the milestone-weighted structure says Lilly knows it.
- Source: Fierce Biotech
- More: CNBC; PR
|
|
2
|
Wainua's full ESC dataset pins the ATTR-CM miss on the stabiliser era
|
- AstraZeneca and Ionis presented primary CARDIO-TTRansform results in Hot Line 1 at ESC Congress 2026 in Munich: eplontersen missed the composite of CV mortality and recurrent CV events at 140 weeks, rate ratio 0.89 (95% CI 0.73–1.09; p=0.277) in 1,432 patients.
- Why it matters: The full dataset gives the miss a mechanism rather than just a headline. 57% of patients were on a TTR stabiliser at baseline and another 24% started one on trial, so roughly four in five were already treated when eplontersen was added. The prespecified monotherapy subgroup came in nominally positive. That reframes the question from whether silencing works to whether it adds anything on top of tafamidis, and it lands directly on Alnylam, whose HELIOS-B win for Amvuttra was generated in a lighter-stabiliser era. Ionis carries the sharper single-asset exposure; AstraZeneca absorbs it inside a far larger book.
-
Source:
STAT
-
More:
Endpoints; Fierce Pharma; BioCentury
|
| 3 | FDA approves Mimrylo, triggering $275M to Protagonist |
-
FDA approved Mimrylo (rusfertide) for erythrocytosis in adults with polycythemia vera on Friday, clearing the first hepcidin mimetic in the indication on Phase 3 VERIFY data.
- Why it matters: Approval triggers $275M to Protagonist immediately — a $200M opt-out fee plus a $75M approval milestone — with up to $875M more in milestones and tiered royalties of 14–29%, roughly 21% weighted. That is unusually rich for a company that handed commercialisation to Takeda in April, and it converts PTGX into a royalty stream carrying no launch spend. VERIFY delivered 76.9% clinical response versus 32.9% on placebo at Weeks 20–32 in 293 patients. The market is around 90,000 US patients still managed largely by phlebotomy and cytoreductive therapy, so the variable is displacement speed, not efficacy.
- Source: Endpoints
- More: STAT; Fierce Pharma
|
Everything Else that broke
- Cytokinetics' aficamten met both dual primary endpoints in ACACIA-HCM, the first positive Phase 3 in non-obstructive HCM, with 53% of patients responding on three or more measures at Week 36 versus 13% on placebo; sNDA planned for Q4. — GlobeNewswire
- FDA cleared Mounjaro to reduce MACE in adults with type 2 diabetes at high CV risk, on SURPASS-CVOT non-inferiority to Trulicity across 13,299 patients in 30 countries. — Fierce Pharma
- BioNTech and Genentech scrapped autogene cevumeran's Phase 2 in colorectal cancer after the personalised mRNA vaccine recorded more deaths than control, a standalone-monotherapy setback that leaves Merck and Moderna's Keytruda-paired intismeran as the modality's only Phase 3 win. — Fierce Biotech
- Karyopharm filed an FDA sNDA for XPOVIO plus ruxolitinib in myelofibrosis. — PR
- IDEAYA said FDA backed Phase 3 design for IDE849 in extensive stage small cell lung cancer. — PR
- Lilly reported one-year Phase 3b data favoring Taltz plus Zepbound over Taltz alone at Week 36. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Lilly will acquire Merida Biosciences for up to $2.875B in cash, inclusive of upfront and contingent milestones, adding MER511 and an antibody-degradation platform in autoimmune and allergic disease; close expected Q4 2026. — PR
- BioXcel Therapeutics filed for bankruptcy and lined up Teva as stalking horse bidder for its neuroscience portfolio at $57.5M upfront, up to $125M in total consideration. — Fierce Biotech
- RedHill sold Talicia to Apotex for $18M upfront plus milestones. — PR
- Samsung Biologics published the prospectus for its tender offer for PolyPeptide, valuing the peptide CDMO at about CHF 1.46B. — PR
VC / Private Financings
- No notable private financings since the last edition.
IPOs / Follow-Ons
- No notable IPOs / follow-ons since the last edition.
Academic Corner - Macropinocytosis-mediated recyclable LYTACs drove receptor-independent protein degradation in a new Nature Biotechnology paper. — Nature Biotech
- Nature Medicine published a secondary analysis of eplontersen in ATTR-CM with and without background stabilizers. — Nature Medicine
- ASPIRED found immediate 14-day ECG monitoring after unexplained syncope did not significantly cut one-year patient-reported episodes versus standard care, presented in Hot Line 10 at ESC. — NEJM
|
Lilly bought the antibodies, ESC broke the thesis, and Munich gets its ballroom back. — BioBucks Team
|
|
|
